Introduction
============

Acute myeloid leukemia (AML) is an aggressive hematological disease that is characterized by the overproduction of early myeloid precursor cells, often to the exclusion of other cell lines. It leads to anemia, thrombocytopenia, and neutropenia,[@b1-cmar-10-2457],[@b2-cmar-10-2457] all of which typically have poor outcomes. Recently, some significant improvements have been achieved in our understanding of AML biology and genetics. These fundamental discoveries are now being translated into new diagnostic and therapeutic strategies for this disease.[@b3-cmar-10-2457]

One of the commonly mutated genes in AML is *DNMT3A*. It encodes a DNA methyltransferase that is localized in the cytoplasm and nucleus, and plays a role in de novo methylation. The prevalence of mutations in *DNMT3A* ranges from 18% to 36% in AML.[@b4-cmar-10-2457],[@b5-cmar-10-2457] Hajkova et al found significantly lower levels of global DNA methylation in AML patients with *DNMT3A* mutations, and this hypomethylation correlated with higher relapse rates and poorer overall survival (OS).[@b6-cmar-10-2457] Many recent studies have also suggested that the *DNMT3A* mutation should be considered a poor prognostic factor in AML.[@b5-cmar-10-2457]--[@b9-cmar-10-2457] The frequencies of *IDH1* and *IDH2* mutations in AML are approximately 6--16% and 8--19%, respectively.[@b10-cmar-10-2457],[@b11-cmar-10-2457] IDH is an essential metabolic enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-KG. The *IDH1/2* gene mutations give rise to reduced levels of α-KG and increased levels of 2HG.[@b10-cmar-10-2457],[@b12-cmar-10-2457] In AML, increasing cellular 2HG levels will inhibit α-KG-dependent enzymes that are important for the demethylation of DNA.[@b10-cmar-10-2457],[@b13-cmar-10-2457],[@b14-cmar-10-2457] Studies have shown that *IDH1/2*^mut^ display global DNA hypermethylation, and in hematopoietic stem cells, expression of mutant *IDH1/2* increases the expression of stem cell markers and impaired myeloid differentiation.[@b15-cmar-10-2457] A recent meta-analysis indicated that *IDH1* mutations confer a poorer OS and event-free survival (EFS). However, for *IDH2*, some differences were noted. The *IDH2*^R140^ mutations were associated with better OS among younger cases, whereas outcome was poor for patients with the *IDH2^R172^* mutation.[@b10-cmar-10-2457],[@b16-cmar-10-2457]

Mutations in *DNMT3A* and *IDH1/2* have a significant effect on the prognosis of AML patients. They are both involved in the epigenetic regulation of transcription, particularly, alterations in DNA methylation. In addition, these genes both show a high co-mutation rate. However, whether the pattern of association between *DNMT3A*^mut^ and *IDH1/2*^mut^ suggests an interplay in the prognosis of AML remains unknown. This study aims to determine whether *IDH1/2* influences the outcomes of AML patients with the *DNMT3A* mutation, and its effects.

Patients and methods
====================

Patients
--------

Fifty-one patients diagnosed with AML and the *DNMT3A* mutation were enrolled in the study. Experimental data were derived from The Cancer Genome Atlas database (<https://cancergenome.nih.gov/>). Data on demographic and molecular characteristics of patients with AML, EFS, OS, etc. were also collected and analyzed. Recurrent genetic mutations were detected by next-generation sequencing. Patients were treated in accordance with national comprehensive cancer network guidelines (<https://www.nccn.org>), with an emphasis on enrollment in therapeutic clinical trials wherever possible. Patients with poor risk received allogeneic hematopoietic stem cell transplantation (allo-HSCT) if they were medically fit for the associated risks of transplantation, and if a suitably matched donor was available. Many patients with intermediate risk also underwent allo-HSCT at some point during the course of the disease.[@b17-cmar-10-2457] Four patients with intermediate risk received autogenic hematopoietic stem cell transplantation (auto-HSCT). Nineteen patients received allo-HSCT, among which 9 received sibling allo-HSCT (2 high-risk patients and 7 intermediate-risk patients), 6 received matched unrelated donor (MUD) HSCT (1 high-risk patient and 5 intermediate-risk patients), 3 received auto- and MUD HSCT (1 high-risk patient and 2 intermediate-risk patients), and 1 intermediate-risk patient received auto- and sibling allo-HSCT.

To further support the analysis, we used the data of patients in the Clinseq cohort.[@b18-cmar-10-2457] There were 63 patients with the *DNMT3A* mutation in the Clinseq cohort who were diagnosed between February 1997 and August 2014. Bone marrow or peripheral blood samples were obtained at the time of diagnosis. These patients were treated with intensive induction regimens, including anthracyclines and cytosine arabinoside, according to national guidelines.[@b19-cmar-10-2457]

Statistical analysis
--------------------

The primary study endpoints were EFS and OS. The EFS was defined as that time from the date of diagnosis to removal from the study, owing to the absence of complete remission, relapse, or death. The OS was defined as that time from the date of diagnosis to death by any cause. For patients in the Clinseq cohort, we considered OS as the primary outcome.

The demographics and characteristics of the subjects were summarized using descriptive statistics. Intergroup difference was performed using the Student's *t*-test and chi-square test. Survival analyses were performed using the Kaplan--Meier method. A two-sided *P*-value \<0.05 was considered statistically significant. All statistical analyses were performed with the SPSS software 20.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Demographic and biological characteristics
------------------------------------------

The mutation rates of *IDH* are shown in [Figure 1](#f1-cmar-10-2457){ref-type="fig"}. Sixteen patients had either the *IDH1* or *IDH2* mutation, accounting for 31.4%. The *IDH1* mutations were observed more frequently than *IDH2* mutations. Eleven patients with the *IDH1* mutation had a mutation at R132. Three patients with the *IDH2*-mutation had an *IDH2^R140^* mutation, and the other 2 had an *IDH2^R172^* mutation.

The demographic and biological characteristics and the intergroup differences are summarized in [Table 1](#t1-cmar-10-2457){ref-type="table"}. The median age among all 51 patients was 58 years (range: 21--81 years); 27 patients (52.9%) were younger than 60 years. The subjects included 24 males (47.1%) and 27 females (52.9%). In AML FAB, patients with a subtype of M1, 9 (17.6%) of them had *DNMT3A* and *IDH1/2* double mutations while only 4 (7.8%) had only *DNMT3A*^mut^ (*P*=0.001). The median white blood cell (WBC) count was 45×10^9^/L (range: 1.2×10^9^/L--298.4×10^9^/L), and 19 cases (37.3%) had counts ≥ 50×10^9^/L WBC. The median percentages of bone marrow (BM) blasts and peripheral blood (PB) blasts were 76% (range: 32--100%) and 36% (range, 0--97%), respectively. The percentages of BM blasts and PB blasts in 30 cases (58.8%) and 15 cases (30.0%), respectively, were ≥ 70%. Twenty-eight patients (54.9%) relapsed after receiving treatment. However, these characteristics showed no significant differences between the *DNMT3A*^mut^*IDH1/2*^wild^ and *DNMT3A*^mut^*IDH1/2*^mut^ groups.

The mutation status of the genes under investigation is summarized in [Table 1](#t1-cmar-10-2457){ref-type="table"}. All genes were associated with AML and had a mutation rate \> 5% in our cohort. The most frequently mutated gene was *NPM1*, with 28 mutated cases (54.9%), most of which were concentrated in the *DNMT3A*^mut^*IDH1/2*^wild^ group (*P*=0.022). Other mutations, including those of *FLT3*-ITD/TKD, *TET2*, *SMC3*, *NRAS*, *KRAS*, *CEBPA*, *PTPN11*, *U2AF1*, *SMC1A*, and *RAD21*, showed no significant intergroup differences (*P*\> 0.05). Among the 51 cases, 23 patients (45.1%) underwent HSCT. In the *DNMT3A*^mut^*IDH1/2*^mut^ group, 11 cases accepted HSCT, whereas 5 did not. The proportion of HSCT acceptance was significantly higher in patients with double mutations (*P*=0.022).

Comparison of EFS and OS between the *DNMT3A*^mut^*IDH1/2*^wild^ and *DNMT3A*^mut^*IDH1/2*^mut^ groups
------------------------------------------------------------------------------------------------------

In order to determine which patients were more likely to be affected by the *IDH1/2* mutation, we stratified the data by several aspects, such as age, WBC count, percentages of BM blasts and PB blasts, mutated recurrent gene numbers, and frequently mutated genes, such as *FLT3* and *NPM1*. The results of the Kaplan--Meier analysis for EFS and OS are summarized in [Table 2](#t2-cmar-10-2457){ref-type="table"}. Although the median survival time seemed longer in the double mutation group in several aspects, such as age \<60 years, BM blasts or PB blasts \<70%, *FLT3* mutation absent, and *NPM1* mutation present, no significant differences were observed among any of these characteristics (*P*\> 0.05).

In the entire cohort, no significant differences were observed in EFS or OS of patients between the *DNMT3A*^mut^*IDH1/2*^wild^ and *DNMT3A*^mut^*IDH1/2*^mut^ groups ([Figure 2A and B](#f2-cmar-10-2457){ref-type="fig"}, *P*\> 0.05). We divided the patients into 2 groups according to treatment, and observed no significant differences in either group ([Figure 2C--F](#f2-cmar-10-2457){ref-type="fig"}, *P*\> 0.05). The HSCT showed better efficacy than chemotherapy in the *DNMT3A*^mut^*IDH1/2*^wild^ group, and led to a higher EFS and OS ([Figure 3A and B](#f3-cmar-10-2457){ref-type="fig"}, *P*=0.010 for EFS and *P*=0.007 for OS). However, in the *DNMT3A*^mut^*IDH1/2*^mut^ group, no significant differences were observed between the two treatment methods ([Figure 3C and D](#f3-cmar-10-2457){ref-type="fig"}, *P*\> 0.05).

Considering the differences in effect of *IDH1* and *IDH2* mutations on the prognosis of patients, we divided the entire cohort into 3 groups, more specifically the *IDH1/2*^wild^, *IDH1* mutation and *IDH2* mutation groups. We did not separate *IDH2^R140^* and *IDH2^R172^* mutations because of the small sample size. The results of Kaplan--Meier analysis for EFS and OS are shown in [Figure 4A--D](#f4-cmar-10-2457){ref-type="fig"} (*P*\>0.05). No significant differences were observed among the 3 groups.

We further verified our results in the Clinseq cohort. When patients with mutations of *IDH1* or *IDH2* were grouped together, the results of Kaplan--Meier analysis for OS showed no significant differences between the *DNMT3A*^mut^*IDH1/2*^wild^ and *DNMT3A*^mut^*IDH1/2*^mut^ groups ([Figure 5A](#f5-cmar-10-2457){ref-type="fig"}, *P*=0.128). In [Figure 5B](#f5-cmar-10-2457){ref-type="fig"}, patients with the *IDH2^R140^* mutation were considered a single group. Furthermore, because of their relatively consistent effects on the prognosis, patients with mutations of *IDH1* and *IDH2^R172^* were divided into 2 groups. No significant differences were observed in the OS among these 3 groups (*P=0.124*).

Discussion
==========

We synthetically analyzed different aspects of the effects of *IDH1/2*^mut^ on the outcomes of patients with *DNMT3A*-mutated AML; however, no significant differences were found. The HSCT could be a more favorable option for patients with the *DNMT3A* mutation. However, HSCT and chemotherapy showed no significant differences in patients with double mutations. The *DNMT3A*^mut^*IDH1/2*^mut^ group showed relatively lower rates of *NPM1* mutation.

Previous studies have indicated that *NPM1* and double-mutated *CEBPA* have positive effects, whereas *FLT3*-ITD, *TET2*, *KRAS*, *PTPN11*, *U2AF1*, and *MLL*-PTD mutations have adverse effects on the outcomes of AML patients.[@b20-cmar-10-2457]--[@b27-cmar-10-2457] Mutations of *SMC3*, *RAD21*, and *NRAS* were thought to have little to no influence on those studies, whereas the effects of other gene mutations, such as that of *SMC1A*, on the prognosis of AML had not been clearly determined.[@b20-cmar-10-2457]--[@b27-cmar-10-2457]

In our cohort, 54.9% of the patients had *NPM1* mutations. Patients in the *DNMT3A*^mut^*IDH1/2*^mut^ group had a lower mutation rate of *NPM1* (45.1% versus 9.8%). In another study, about 80% of *DNMT3A*-mutated patients had *NPM1* mutations, and 65.4% of the double-mutation patients concurrently harbored *NPM1* mutations.[@b8-cmar-10-2457] Rakheja et al indicated that *IDH1^R132^* and *IDH2^R140^* mutations are frequently accompanied by *NPM1* mutations in AML.[@b10-cmar-10-2457] In our cohort, 87.5% of the patients harbored *IDH1^R132^* or *IDH2^R140^*; however, we observed no correlation between *NPM1* and *IDH1/2*. The reason for this difference might be due to the age distribution of the sample, the small sample size, or the research background of our cohort.

Many studies have attempted to elucidate the effects of multiple gene mutations on the outcomes of AML. More specifically, studies have shown that *FLT3*-ITD with the *DNMT3A^R882^* double mutation is a poor prognostic factor in AML;[@b28-cmar-10-2457] whereas *NPM1* mutations do not seem to have a significant effect on the outcomes of patients with *DNMT3A*-mutated AML.[@b8-cmar-10-2457] Alternatively, *IDH1/2*^mut^ constitute a poor prognostic factor in *NPM1*-mutated cytogenetically normal-AML (CN-AML) without *FLT3-ITD*.[@b29-cmar-10-2457] Our study revealed that *IDH1/2*^mut^ have little influence on the outcomes of patients with *DNMT3A*-mutated AML.

The HSCT has been confirmed as an effective therapy for intermediate- or high-risk patients with AML. Patients at higher risk usually benefit more from transplant therapy. The survival of CN-AML patients with *DNMT3A*^mut^ could be improved following allo-HSCT.[@b30-cmar-10-2457] Nevertheless, as we have mentioned before, the *FLT3*-ITD and *DNMT3A^R882^* double mutation is a poor prognostic factor in AML. Patients with this condition have significantly lower 2-year OS and leukemia-free survival (the duration from post-transplantation to recurrence of leukemia or death) following allo-HSCT, than patients with single *FLT3*-ITD or *DNMT3A*^mut^.[@b28-cmar-10-2457]

In comparison with chemotherapy, our results demonstrate that HSCT had a more favorable therapeutic effect on patients with the *DNMT3A* mutation. When *IDH1/2*^mut^ were taken into account however, the effects of these two therapies were statistically equivalent. Patients with the *DNMT3A* and *IDH1/2* double mutation showed no gain in EFS or OS after either HSCT or chemotherapy. This result suggests that *IDH1/2*^mut^ might not be a strong biomarker for HSCT therapy in patients with the *DNMT3A* mutation. Analysis of data from the Clinseq cohort further supported the view that *IDH1/2*^mut^ in patients with AML who received chemotherapy had little effect on the outcomes of those with the *DNMT3A* mutation. The results of the analysis in which different mutations of *IDH* were separated also showed that they had no impact on the prognosis of these patients, even though mutations of *IDH1*, *IDH2^R140^*, and *IDH2^R172^* might have different effects on the outcome.

In addition to HSCT, targeted therapy is now one of the more popular treatment choices that can show good efficacy. Enasidenib (AG-221) is a reversible and selective inhibitor of mutant *IDH2*.[@b3-cmar-10-2457],[@b31-cmar-10-2457],[@b32-cmar-10-2457] Inhibitors of *IDH1*, such as AG-120 and IDH305, are also under investigation.[@b3-cmar-10-2457] Although our study showed that *IDH1/2*^mut^ have no influence on the outcomes of AML patients with *DNMT3A*^mut^, because of the development of novel, effective target drugs, *IDH1/2* inhibitors might have positive effects on the overall prognosis of patients with double mutations.

Limitations
===========

Several limitations of the present study need to be acknowledged. Our study is a retrospective study with a relatively small sample size, and some bias needs to be considered. In some groups, the number of samples was less than 5, thus limiting further statistical analysis. Therefore, the present results need to be verified in larger cohorts.

Conclusion
==========

We propose that *IDH1/2* has no impact on the prognosis of AML patients with the *DNMT3A* mutation. Furthermore, HSCT showed a more favorable therapeutic effect for patients with the *DNMT3A*, but without the *IDH1/2* mutation. For patients with double mutations, the efficacy of HSCT was similar to that of chemotherapy.
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![Mutation rate of *IDH*.\
**Note:** Total mutation frequency of *IDH1/2* was 31.4% (16 cases); 21.6% (11 cases) for *IDH1* and 9.8% (5 cases) for *IDH2*.](cmar-10-2457Fig1){#f1-cmar-10-2457}

![Kaplan--Meier analysis of EFS and OS.\
**Notes:** (**A**,**B**) *IDH1/2* mutation status had no effect on EFS or OS in the whole cohort. (**C**,**D**) *IDH1/2* mutation status had no effect on EFS or OS for the patients subjected to chemotherapy. (**E**,**F**) *IDH1/2* mutation status had no effect on EFS or OS for the patients subjected to HSCT.\
**Abbreviations:** EFS, event-free survival; OS, overall survival; HSCT, hematopoietic stem cell transplantation.](cmar-10-2457Fig2){#f2-cmar-10-2457}

![Patient responses to treatment.\
**Notes:** (**A**,**B**) HSCT had a better therapeutic effect for patients with the *DNMT3A*^mut^ and *IDH1/2*^wild^. (**C**,**D**) For the patients with both *DNMT3A* and *IDH1/2*^mut^, HSCT and chemotherapy were considered to have similar efficacy.\
**Abbreviations:** HSCT, hematopoietic stem cell transplantation; mut, mutation; wild, wild type.](cmar-10-2457Fig3){#f3-cmar-10-2457}

![Patient responses to treatment.\
**Notes:** (**A**,**B**) *IDH1* and *IDH2* mutation status had no effect on EFS or OS in the whole cohort. (**C**,**D**) *IDH1* and *IDH2* mutation status had no effect on EFS or OS for patients subjected to HSCT.\
**Abbreviations:** EFS, event-free survival; OS, overall survival; HSCT, hematopoietic stem cell transplantation.](cmar-10-2457Fig4){#f4-cmar-10-2457}

![Kaplan--Meier analysis of OS of patients from the Clinseq cohort.\
**Notes:** (**A**) *IDH1/2* mutation status had no effect on OS in the whole cohort. (**B**) Different mutations of *IDH* had no effect on OS for patients in the whole cohort.\
**Abbreviation:** OS, overall survival.](cmar-10-2457Fig5){#f5-cmar-10-2457}

###### 

Clinical and molecular characteristics of patients

  Characteristics           Median (range) or n/%   Intergroup difference                                                                            
  ------------------------- ----------------------- ----------------------- ------------------- ---------------------------------------------------- -------
  Age (years)               58 (21--81)             59 (21--81)             57.5 (42--69)       0.528[\^](#tfn1-cmar-10-2457){ref-type="table-fn"}   0.600
   \<60                     27/52.9                 18/35.3                 9/17.6                                                                   
   ≥ 60                     24/47.1                 17/33.3                 7/13.7                                                                   
  Gender                                                                                        0.102[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.749
   Male                     24/47.1                 17/33.3                 7/13.7                                                                   
   Female                   27/52.9                 18/35.3                 9/17.6                                                                   
  AML FAB subtypes                                                                                                                                   
   M0                       3/5.9                   1/2.0                   2/3.9               1.844[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.229
   M1                       13/25.5                 4/7.8                   9/17.6              11.615[§](#tfn2-cmar-10-2457){ref-type="table-fn"}   0.001
   M2                       11/21.6                 9/17.9                  2/3.9               1.133[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.466
   M4                       12/23.5                 10/19.6                 2/3.9               1.576[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.296
   M5                       11/21.6                 10/19.6                 1/2.0               3.234[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.140
   M7                       1/1.9                   1/2.0                   0                   0.466[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
  WBC count/×10^9^/L        45 (1.2--298.4)         45.3 (1.4--298.4)       15.2 (1.2--171.9)   1.515[\^](#tfn1-cmar-10-2457){ref-type="table-fn"}   0.136
   \<50                     32/62.7                 19/37.3                 13/25.5                                                                  
   ≥ 50                     19/37.3                 16/31.4                 3/5.9                                                                    
  BM blasts/%               76 (32--100)            74 (32--100)            81.5 (42--99)       1.427[\^](#tfn1-cmar-10-2457){ref-type="table-fn"}   0.160
   \<70                     21/41.2                 17/33.3                 4/7.8                                                                    
   ≥ 70                     30/58.8                 18/35.3                 12/23.5                                                                  
  PB blasts/%               36 (0--97)              16.5 (0--96)            51.5 (6--97)        1.859[\^](#tfn1-cmar-10-2457){ref-type="table-fn"}   0.069
   \<70                     35/70.0                 25/50.0                 10/20.0                                                                  
   ≥ 70                     15/30.0                 9/18.0                  6/12.0                                                                   
  Relapse                                                                                       0.017[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Yes                      28/54.9                 19/37.3                 9/18.0                                                                   
   No                       23/45.1                 16/31.4                 7/13.7                                                                   
  Mutated recurrent genes   6 (2--11)                                                           1.670[\^](#tfn1-cmar-10-2457){ref-type="table-fn"}   0.102
   \<5                      15/29.4                 15/29.4                 0                                                                        
   ≥ 5                      36/70.6                 20/39.2                 16/31.4                                                                  
  *NPM1*                                                                                        5.268[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.022
   W288                     26/51.0                 22/43.1                 4/7.8                                                                    
   Others                   2/3.9                   1/2.0                   1/2.0                                                                    
   Wild type                23/45.1                 12/23.5                 11/21.6                                                                  
  *FLT3*                                                                                        2.519[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.112
   *FLT3*-ITD               12/23.5                 11/21.6                 1/2.0                                                                    
   *FLT3*-TKD               9/17.6                  6/11.8                  3/5.9                                                                    
   Wild type                30/58.8                 18/35.3                 12/23.5                                                                  
  *TET2*                                                                                        0.012[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Mutation                 6/11.8                  4/7.8                   2/3.9                                                                    
   Wild type                45/88.2                 31/60.8                 14/27.5                                                                  
  *SMC3*                                                                                        3.109[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.159
   Mutation                 6/11.8                  6/11.8                  0                                                                        
   Wild type                45/88.2                 29/56.9                 16/31.4                                                                  
  *NRAS*                                                                                        0.333[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Mutation                 5/9.8                   4/7.8                   1/2.0                                                                    
   Wild type                46/90.2                 31/60.8                 15/29.4                                                                  
  *KRAS*                                                                                        0.700[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.581
   Mutation                 4/7.8                   2/3.9                   2/3.9                                                                    
   Wild type                47/92.2                 33/64.7                 14/27.5                                                                  
  *CEBPA*                                                                                                                                            
   Single mutation          2/3.9                   1/2.0                   1/2.0               0.335[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.533
   Double mutation          1/2.0                   1/2.0                   0                   0.466[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Wild type                48/94.1                 33/64.7                 15/29.4                                                                  
  *PTPN11*                                                                                      1.844[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.229
   Mutation                 3/5.9                   1/2.0                   2/3.9                                                                    
   Wild type                48/94.1                 34/66.7                 14/27.5                                                                  
  *U2AF1*                                                                                       1.457[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.543
   Mutation                 3/5.9                   3/5.9                   0                                                                        
   Wild type                48/94.1                 32/62.7                 16/31.4                                                                  
  *SMC1A*                                                                                       0.006[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Mutation                 3/5.9                   2/3.9                   1/2.0                                                                    
   Wild type                48/94.1                 33/64.7                 15/29.4                                                                  
  *RAD21*                                                                                       1.457[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.543
   Mutation                 3/5.9                   3/5.9                   0                                                                        
   Wild type                48/94.1                 32/62.7                 16/31.4                                                                  
  *MLL*-PTD                                                                                     0.006[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    1.000
   Presence                 3/5.9                   2/3.9                   1/2.0                                                                    
   Absence                  48/94.1                 33/64.7                 15/29.4                                                                  
  HSCT                                                                                          5.268[§](#tfn2-cmar-10-2457){ref-type="table-fn"}    0.022
   Yes                      23/45.1                 12/23.5                 11/21.6                                                                  
   Allo-HSCT                19/37.3                 9/17.6                  10/19.6                                                                  
   Auto-HSCT                4/7.8                   3/5.9                   1/2.0                                                                    
   None                     28/54.9                 23/45.1                 5/9.8                                                                    

**Notes:**

Student's *t*-test;

chi-square test.

**Abbreviations:** AML FAB, the French-American-British classification of acute myeloid leukemia; WBC, white blood cell; BM, bone marrow; PB, peripheral blood; ITD, internal tandem duplication; TKD, tyrosine kinase domain; HSCT, hematopoietic stem cell transplantation; Allo-HSCT, allogeneic-hematopoietic stem cell transplantation; Auto-HSCT, autogenic-hematopoietic stem cell transplantation; mut, mutation; wild, wild type.

###### 

Comparison of EFS and OS between *DNMT3A*^mut^*IDH1/2*^wild^ and *DNMT3A*^mut^*IDH1/2*^mut^ groups

  Prognostic factor         EFS   OS                                             
  ------------------------- ----- ------ --------- ------- ------ ------ ------- -------
  Age                                                                            
   \<60 years               8.5   14.9   0.225     0.635   16.3   24.8   0.186   0.667
   ≥ 60 years               6.9   4.9    0.619     0.431   8.1    7.8    2.228   0.136
  WBC                                                                            
   \<50×10^9^/L             8.4   13.8   0.732     0.392   10.2   21.5   0.795   0.373
   ≥ 50×10^9^/L             8.1   17.2   1.108     0.293   10.2   27.1   0.647   0.421
  BM blasts                                                                      
   \<70%                    8.4   14.9   1.432     0.231   10.2   28.4   1.601   0.206
   ≥ 70%                    6.4   5.2    0.490     0.484   7.5    12.0   1.055   0.304
  PB blasts                                                                      
   \<70%                    8.1   13.8   0.622     0.430   9.9    21.5   1.815   0.178
   ≥ 70%                    7.5   2.7    0.212     0.645   7.5    6.6    0.243   0.622
  Mutated recurrent genes                                                        
   ≥ 5                      8.2   8.7    1.238     0.266   9.9    20.1   2.570   0.109
  *NPM1*                                                                         
   Mutated                  6.9   13.8   2.084     0.149   7.5    24.8   2.623   0.105
   Wild type                8.5   8.6    \<0.001   0.998   14.6   20.1   0.001   0.972
  *FLT3*-ITD/TKD                                                                 
   Present                  6.9   2.7    0.066     0.798   7.9    6.6    0.012   0.913
   Absent                   8.4   13.8   0.980     0.322   10.2   21.5   1.129   0.288
  HSCT                                                                           
   Yes                      9.9   14.9   0.003     0.960   16.4   24.8   0.010   0.921
   None                     5.9   5.2    0.287     0.592   7.7    5.2    0.116   0.734

**Abbreviations:** EFS, event-free survival; OS, overall survival; WBC, white blood cell; BM, bone marrow; PB, peripheral blood; ITD/TKD, internal tandem duplication and tyrosine kinase domain; HSCT, hematopoietic stem cell transplantation; mut, mutation; wild, wild type.
